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1. Introduction 
1.1 Technique of nigrostriatal FP-CIT SPECT 
The density of the presynaptic dopamine reuptake transporters (DAT) can be quantified 
with [123I]FP-CIT SPECT. The tracer Fluorpropyl-Carbomethoxy-Iodophenyl-Tropan (FP-
CIT), marked by radioactive 123iodine [123I] (therefore the name [123I]FP-CIT), binds 
reversibly to the DAT on the presynaptic membrane. Before application of FP-CIT, the 
iodine uptake of the thyroid gland is blocked with sodium perchlorate. Then the radioactive 
tracer [123I]FP-CIT (110 - 185 MBq, specific activity: 580 - 1040 GBq/mg) is injected 
intravenously. 3 – 6 hours following the intravenous tracer injection, cerebral SPECT images 
are obtained by a gamma camera. At the moment, FP-CIT is the preferred tracer to visualize 
DAT due to its pharmacokinetic properties including fast (3 - 6 hours after intravenous 
injection) and highly affine binding (Ki = 3.1 nM) at DAT (4, 22). The exposure to radiation 
at the examination of an individual with a body weight of 70 kilograms amounts to 4.35 
milli-Sievert (mSv). For comparison: the average effective exposure to natural background 
radiation in middle Europe at sea level runs up to 2.4 mSv. 
Due to the similarity between dopamine reuptake transporters and serotonin reuptake 
transporters, serotonin reuptake inhibitors, widely used as antidepressants, must not be 
taken in the last two weeks before FP-CIT SPECT examination (fluoxetine for a period of 
six weeks). Furthermore therapy with selegiline should be discontinued to avoid 
interaction of its metabolites with FP-CIT at the dopamine transporter (19). Further anti-
parkinsonian medication may be continued during SPECT examination, since present 
data (11, 16, 19, 21) do not show any effect of antiparkinsonian drugs on dopamine 
transporter binding.  
Beyond FP-CIT-SPECT there exist further nuclear medicine methods to quantify the 
nigrostriatal presynaptic DAT density: [123I]-beta-CIT SPECT (2beta-Carbomethoxy-
Iodophenyl-Tropan; late SPECT after application of beta-CIT; [9, 15, 16]) and TRODAT 
SPECT (6, 23). 
2. Evaluation of nigrostriatal FP-CIT SPECT 
Registration and semiquantitative analysis are performed on a workstation. The caudate 
nucleus, putamen and occipital lobe binding of [123I]FP-CIT is assessed semiquantitatively 
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by a regions of interest (ROI) technique. The work station performs an automatic fitting of 
the studies to a model database. This fitting is controlled by an experienced nuclear 
medicine physician and if necessary manually adjusted. The special binding ratios of caudate 
nucleus / occipital lobe and putamen / occipital lobe are calculated. The quotients [caudate nucleus 
binding / occipital lobe binding] and [putamen binding / occipital lobe binding] for both sides are 
calculated. The occipital lobe serves as reference region. In healthy people these quotients 
amount to 3 up to 4.  
FP-CIT SPECT has to be considered as pathological, if 1) absolute FP-CIT binding into 
putamen or caudate nucleus remains below a lower norm value or 2) side-to-side difference 
(right versus left or vice versa) exceeds an upper norm value. The norm values of the 
department of Nuclear Medicine of the Saarland University were obtained in healthy 
volunteers without any present or previous neurological or psychiatric disease (age 38 - 76 
years, 59 ± 11 years, mean ±  SD). In these volunteers the ratio putamen / occipital lobe binding 
was 3.44 ± 0.35 (resulting norm value = mean – 2 SD: ≥ 2.74) for the right putamen and 3.52 ± 
0.36 (norm value ≥ 2.80) for the left putamen. The ratio caudate nucleus / occipital lobe binding 
was 3.67 ± 0.36 (norm value ≥ 2.95) for the right caudate nucleus and 3.67 ± 0.37 (norm value 
≥ 2.93) for the left caudate nucleus. The norm value for the side-to-side difference (affected 
versus unaffected striatal area) is ≤ ∆0.15 (mean + 2 SD; [25]).  
3. Clinical impact of FP-CIT SPECT  
With reference to the definite post-mortem histopathological diagnosis of PD, the UK Brain 
Bank criteria (13) disclose a predictive value for PD of 90%. However, 10% of real PD 
patients (“real” means: with regard to the definite post-mortem histopathological diagnosis) 
1) are not diagnosed as having PD or 2) make the differential diagnostic difficult even for 
experienced neurologists (13, 14). Therefore additional apparative measurements are 
necessary that support the clinical PD diagnosis. At the moment, the nuclear medicine 
measurement of DAT density, which is reduced in PD, represents one of the best apparative 
methods to clarify the PD diagnosis. Primarily the [123I]FP-CIT SPECT represents an 
established method to quantify the nigrostriatal DAT density. 
Motor symptoms of PD are based on a functional loss of the presynaptic dopaminergic 
nigrostriatal neuron. This functional loss correlates inversely with the DAT density on the 
membrane of the presynaptic neuron. Thus, a reduced nigrostriatal DAT density is typical 
for PD (Figures 1 and 2). FP-CIT SPECT correlates significantly with the extent of motor PD 
symptoms (2, 5, 25). At all PD stages presynaptic dopaminergic degeneration is more 
advanced in the putamen than that in the caudate nucleus (10, 25). The test-retest reliability 
of FP-CIT SPECT in PD patients is very high (26).  
The prognostic validity of FP-CIT concerning the clinical progression of PD is unclear. 
Djaldetti et al. (8) applied FP-CIT SPECT in 19 patients with early PD and observed the 
following 12-15 months: striatal [123-I]FP-CIT uptake correlated significantly with the 
progression of motor symptoms ( = difference [motor symptom at follow-up visit] – [motor 
symptom at baseline visit] ) within these 12 – 15 months. These results suggest that a single 
SPECT may predict the disease severity over a period of 12 – 15 months. In contrast, another 
study (12) reported that the FP-CIT SPECT does not allow forecasting the progress of motor 
symptoms of PD over a longer time period of 3-7 years. 
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Fig. 1. FP-CIT SPECT in a patient with PD of the tremor dominant type. The striatal FP-CIT 
uptake is reduced bilaterally. 
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Fig. 2. FP-CIT SPECT in a patient with PD of the hypokinetic rigid type. The striatal FP-CIT 
uptake is bilaterally more reduced than in Figure 1. 
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4. Sensitivity, specificity and predictive value of FP-CIT SPECT  
A multicenter study with 158 PD patients, 27 patients with essential tremor and 35 
healthy volunteers reported a sensitivity of FP-CIT SPECT concerning PD of 95% (2, 3). 
Already in the earliest stage of PD, the sensitivity of the FP-CIT SPECT reaches between 
95% and 100% (10, 18, 25) and amounts to nearly 100% in the more advanced stages of PD 
(24).  
The differentiation between PD and essential tremor represents the main clinical indication 
for the FP-CIT SPECT. The specificity of FP-CIT SPECT concerning PD versus essential 
tremor is high (100%, [3]). In contrast to this, specificity of FP-CIT SPECT against atypical 
parkinsonian syndromes is very low. The term “atypical parkinsonian syndromes” (APS) 
denotes idiopathic neurodegenerative disorders, clinically characterized by a combination of 
an akinetic rigid symptoms with additional symptoms, which are different from those in 
PD. The group of APS includes the multiple system atrophy, the corticobasal degeneration 
and the progressive supranuclear palsy. In contrast to PD, which is induced by a 
presynaptic nigrostriatal dopaminergic degeneration, the APS are based on a postsynaptic 
nigrostriatal dopaminergic degeneration. This postsynaptic degeneration in the APS is 
followed by a secondarily reduced density of presynaptic DAT. Since the DAT density is 
secondarily impaired in the APS, the FP-CIT SPECT cannot sufficiently differentiate 
between APS and PD (1, 17, 20).  
5. Scientific impact of FP-CIT SPECT 
As explained above, FP-CIT SPECT measures the density of presynaptic dopamine reuptake 
transporters. This means that FP-CIT SPECT reflects exactly the underlying 
pathophysiology of PD. This allows further insights into the pathophysiological processes of 
PD. In the following we present some of these insights. 
Recent studies found that the reduction of dopaminergic function – quantified by FP-CIT 
SPECT – correlates significantly with the extent of parkinsonian cardinal symptoms 
bradykinesia and rigidity but not with the extent of tremor in PD (2, 25). PD patients with 
tremor dominant type show a significantly higher striatal FP-CIT uptake than patients with 
akinetic rigid or equivalence type at the same stage of disease (Figure 1 and 2, [25]). These 
findings correlate with the clinical observation that bradykinesia and rigidity respond better 
to levodopa or dopamine agonists than tremor (7). The missing correlation between striatal 
FP-CIT uptake and tremor suggests, that further systems besides the nigrostriatal 
dopaminergic system may contribute to generation of parkinsonian tremor.  
In addition, the FP-CIT SPECT may play an important role in the diagnosis of preclinical 
stage of PD (preclinical means: before first motor symptoms occur). Booij et al. (5) applied 
FP-CIT SPECT in 33 patients with suspected beginning Parkinsonism and performed a 
clinical follow-up of these patients 2-4 years after SPECT imaging. In nine of these 33 
patients, SPECT was pathological; all these nine patients developed PD in the clinical 
follow-up. None of the 24 subjects without normal SPECT developed PD in the clinical 
follow-up. These data suggest a high positive predictive value of the FP-CIT SPECT. A 
study of Filippi et al. (10) involved 29 de-novo PD patients with one-sided clinical 
symptoms and 18 gender- and age-matched controls. In the PD patients, both ipsilateral 
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and contralateral putamen and caudate nucleus showed a significantly reduced FP-CIT 
uptake. The pathological ipsilateral FP-CIT SPECT indicates that a pathological FP-CIT 
SPECT precedes clinical symptoms at the not affected body side. 
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